LCA5

Clinical trials for LCA5 explained in plain language.

Never miss a new study

Get alerted when new LCA5 trials appear

Sign up with your email to follow new studies for LCA5, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

One-Time gene injection aims to rescue sight in rare childhood blindness

Disease control Not yet recruiting

This study tests a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare condition that leads to severe vision loss from a young age. The treatment is given as a single injection under the retina in the worse…

Matched conditions: LCA5

Phase: PHASE1, PHASE2 • Sponsor: Opus Genetics, Inc • Aim: Disease control

Last updated Jul 03, 2026 20:42 UTC

LCA5

Get alerted when new LCA5 trials appear

One-Time gene injection aims to rescue sight in rare childhood blindness